AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6102865
Drug: Flunitrazepam 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.02 mg kg‐1 + atropine 0.03 mg kg‐1
Trial: 6102865
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (Triclofos, Diazepam, Flunitrazepam)
Trial: 6102865
Drug: Triclofos 70
RxNorm normalized name: Triclofos
DrugBank: Triclofos (DB06753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triclofos 70 mg kg‐1
Trial: 6102865
Drug: Diazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.25 mg kg‐1 and Flunitrazepam 0.02 mg kg‐1
Trial: 27415612
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg rosuvastatin (R group, n=26)
Trial: 27415612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n=24)
Trial: 24553480
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral syrup containing paracetamol, phenylephrine hydrochloride, and guaifenesin
Trial: 24553480
Drug: Reference oral
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference oral liquid formulation
Trial: 24553480
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral syrup
Trial: 22442826
Drug: Vildagliptin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (all doses)
Trial: 20980796
Drug: ZOSTAVAX® (zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOSTAVAX® (zoster vaccine) administered concomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Trial: 20980796
Drug: PNEUMOVAX® 23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNEUMOVAX® 23 (pneumococcal vaccine) administered concomitantly with ZOSTAVAX®
Trial: 20980796
Drug: ZOSTAVAX® (zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOSTAVAX® (zoster vaccine) administered nonconcomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Trial: 12635061
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion (2‐4 microg/kg/min) with isoflurane supplementation
Trial: 12635061
Drug: Remifentanil continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil continuous infusions (1‐5 microg/kg/min)
Trial: 1734554
Drug: Tampons impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tampons impregnated with tranexamic acid (TA), three tampons administered at 2-hourly intervals over 6 hours
Trial: 25436480
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment for simple bone cysts (exact intervention details not provided)
Trial: 25436480
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment for simple bone cysts
Trial: 22437191
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus BMX 54 (vaginal application, one tablet once a week for 12 weeks)
Trial: 18327969
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of anesthetic solution
Trial: 18327969
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of anesthetic solution
Trial: 12797909
Drug: ACE-Inhibitors (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-Inhibitors (group 1)
Trial: 12797909
Drug: Diuretics (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (group 2)
Trial: 12797909
Drug: Ca-Antagonists (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-Antagonists (group 3)
Trial: 10334671
Drug: Normalization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normalization of haemoglobin (target 13.5-16.0 g/dl)
Trial: 10334671
Drug: Normalization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normalization of haemoglobin (target 13.0-14.0 g/dl)
Trial: 10334671
Drug: Increase haemoglobin
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase haemoglobin to a mean of 12.5 g/dl
Trial: 10334671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (target haemoglobin 9.5-10.5 g/dl)
Trial: 8729309
Drug: Buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3 mg subcutaneous) on demand (group 1, n = 20)
Trial: 8729309
Drug: Buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3 mg)‐propacetamol (2 g)‐ketoprofen (100 mg) by intravenous route over 2 hours followed by an infusion of propacetamol (2 g) and ketoprofen (100 mg) at a constant rate over 22 hours (group 2, n = 20)
Trial: 8729309
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of buprenorphine (0.3 mg), propacetamol (2 g) and ketoprofen (100 mg) over the same period (group 3, n = 20)
Trial: 27386642
Drug: Yiguanjian Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiguanjian Decoction (YD) combined with Adefovir Dipivoxil Tablet (ADT)
Trial: 27386642
Drug: Adefovir Dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir Dipivoxil Tablet (ADT) alone
Trial: 9220875
Drug: Pain management
RxNorm normalized name: Olu Pain Management 4%-1% Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain management strategies and medications at hospital admission
Trial: 9220875
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antiseptics vs cleansing solutions
Trial: 9220875
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of non-recommended treatments for ulcers
Trial: 8193690
Drug: HBOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC vaccine
Trial: 3812345
Drug: Lowest selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest selenium quintile (< 105.0 micrograms/L)
Trial: 30153780
Drug: Histamine-2 Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 Receptor Blockers (H2RB)
Trial: 24552184
Drug: IN.PACT Amphirion™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN.PACT Amphirion™ paclitaxel drug-eluting balloon (IA-DEB)
Trial: 22681643
Drug: Urethral sparing
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral sparing intensity modulated radiation therapy (US‐IMRT)
Trial: 22681643
Drug: Standard intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensity modulated radiation therapy (S‐IMRT)
Trial: 17667137
Drug: Oral mefenamic
RxNorm normalized name: meclofenamate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mefenamic acid and intramuscular meperidine
Trial: 11452896
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg slow release dipyridamole (DP)
Trial: 11452896
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA plus DP
Trial: 3288723
Drug: High-dose pentobarbital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pentobarbital
Trial: 31657275
Drug: High DCI
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High DCI content group (550 mg MYO + 300 mg DCI daily)
Trial: 31657275
Drug: Low DCI
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low DCI content group (550 mg MYO + 27.6 mg DCI daily)
Trial: 30019528
Drug: dHACA (dehydrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dHACA (dehydrated human amnion and chorion allograft) applied weekly for up to 12 weeks
Trial: 24265819
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses group (20 μg IM at months 0, 1, and 6)
Trial: 24265819
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses group (20 μg IM at months 0, 1, 2, 6)
Trial: 24265819
Drug: Four double
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four double doses group (40 μg IM at months 0, 1, 2, 6)
Trial: 24265819
Drug: Four double
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four double doses group
Trial: 10877734
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of rofecoxib, 250 mg
Trial: 10877734
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of indomethacin, 75 mg
Trial: 10877734
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of rofecoxib, 12.5 mg/d
Trial: 10877734
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of rofecoxib, 25 mg/d
Trial: 10877734
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of indomethacin, 50 mg three times daily
Trial: 9106016
Drug: Azithromycin 3-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 3-day course (10 mg/kg daily)
Trial: 9106016
Drug: Azithromycin 5-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 5-day course (10 mg/kg on day 1 and 5 mg/kg on days 2‐5)
Trial: 3492153
Drug: Nimodipine (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (0.09 mg/kg X h)
Trial: 28560802
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg prednisolone
Trial: 20981001
Drug: Endoxifen, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoxifen, single oral doses ranging from 0.5 to 4.0 mg
Trial: 11850257
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of amprenavir with 100 mg of ritonavir twice daily
Trial: 11850257
Drug: Once-daily regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimens
Trial: 84259
Drug: Alternate-day prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternate-day prednisone (35 mg/m2/48 h)
Trial: 84259
Drug: Intermittent prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent prednisone (40 mg/m2 on three consecutive days out of seven)
Trial: 31107694
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine Training (TCMT) for 12 weeks
Trial: 20869706
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists combined with GnRH antagonists
Trial: 20869706
Drug: GnRH agonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonists alone
Trial: 19560257
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 2000 mg/100 ml of saline
Trial: 19560257
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) 100 ml of saline
Trial: 15001970
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (300 mg tablet, 3 times daily for 14 days)
Trial: 3544754
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg nisoldipine
Trial: 3544754
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nisoldipine
Trial: 31176375
Drug: High-flow oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow oxygen therapy (HFOT) during high-intensity exercise training
Trial: 15527158
Drug: Community-based directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based directly observed treatment (DOT) using guardians and former TB patients
Trial: 15527158
Drug: Health facility-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health facility-based directly observed treatment (DOT)
Trial: 8267425
Drug: EC +
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC + BN 52021 (10 mg/kg)
Trial: 8267425
Drug: EC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC (40 mL/kg)
Trial: 30871934
Drug: Nestorone (NES)
RxNorm normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 10 mcg/day
Trial: 30871934
Drug: Nestorone (NES)
RxNorm normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 20 mcg/day
Trial: 30871934
Drug: Nestorone (NES)
RxNorm normalized name: Ne
DrugBank: Segesterone acetate (DB14583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone (NES) 200 mcg/day and estradiol (E2) 40 mcg/day
Trial: 27887033
Drug: Menthol gel
RxNorm normalized name: MENTHOL GEL,TOP
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol gel
Trial: 27887033
Drug: Reference treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatments (0.9% saline and marketed gel 1% diclofenac, Voltaren)
Trial: 23740384
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml LZD suspension
Trial: 23740384
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg LZD tablet
Trial: 17162142
Drug: Usual-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-protein diet (1.3 g/kg/d)
Trial: 14572566
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L sulfate‐free electrolyte lavage solution (SF‐ELS) plus 20 mg p.o. bisacodyl
Trial: 14572566
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L sulfate-free electrolyte lavage solution (SF‐ELS)
Trial: 2202247
Drug: Furosemide 30
RxNorm normalized name: furosemide 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 30 mg
Trial: 20018483
Drug: Probiotic supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplemented formula (Lactobacillus salivarius CECT5713, 2 × 10(6) cfu/g)
Trial: 15941684
Drug: Glucan treatment
RxNorm normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucan treatment for 12 weeks
Trial: 10848657
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d.
Trial: 16817839
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.d.
Trial: 789219
Drug: Frubienzym (throat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frubienzym (throat lozenges with 5 mg lysozyme, 2 mg papaine and 200 I.U. bacitracin)
Trial: 23801589
Drug: CALM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALM treatment
Trial: 21777477
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (including psychotherapy, pharmaceutical interventions, and group therapy)
Trial: 19623867
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (30-50 mg/kg bolus followed by 500 mg/h continuous infusion)
Trial: 19623867
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (control group)
Trial: 17101743
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg daily
Trial: 17101743
Drug: Varenicline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg daily
Trial: 17101743
Drug: Varenicline 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 3 mg daily
Trial: 17101743
Drug: Varenicline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg twice daily
Trial: 11498066
Drug: Oral crystalline
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral crystalline cyanocobalamin (3000 microg or 5000 microg once a week for at least 3 months)
Trial: 325301
Drug: Guancydine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guancydine (21 mg/kg body weight for 7 to 18 days)
Trial: 24796764
Drug: CC/IUI (Clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC/IUI (Clomiphene Citrate/Intrauterine Insemination)
Trial: 24796764
Drug: FSH/IUI (Follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH/IUI (Follicle Stimulating Hormone/Intrauterine Insemination)
Trial: 15670788
Drug: Haplotype V3‐V4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haplotype V3‐V4 (G‐C)
Trial: 12765846
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acid supplementation (3.6g n‐3 fatty acids/day containing 2.4 g of EPA and DHA)
Trial: 10580781
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (hormone therapy)
Trial: 26232241
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate once-monthly (PP)
Trial: 3106234
Drug: Pseudomonas immunoglobulin
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas immunoglobulin (250 mg/kg body weight, intravenous route, days 3 to 13)
Trial: 29746282
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 500 mg daily
Trial: 27039242
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in relative abundance of insulin-like growth factor binding proteins (IGFBPs) and subclasses of apolipoprotein (Apo) and transthyretin
Trial: 24683583
Drug: In situ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In situ tissue‐engineered graft containing 54 ± 38 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group A)
Trial: 24683583
Drug: In situ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In situ tissue‐engineered graft containing 1,012 ± 752 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group B)
Trial: 20682875
Drug: Albendazole (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (three daily 400-mg doses)
Trial: 15923800
Drug: Prochlorperazine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine (15 mg spansules twice daily)
Trial: 15923800
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg tablets twice daily)
Trial: 15923800
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg tablets twice daily)
Trial: 10994404
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg adenosine
Trial: 10994404
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg adenosine
Trial: 10323120
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia in the anterior mucobuccal fold
Trial: 1462581
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg propranolol retard in one dose daily for 10 days
Trial: 30374831
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine digluconate and 0.2% sodium hyaluronate treatment
Trial: 30374831
Drug: Neutral solution
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral solution (placebo)
Trial: 27099245
Drug: Fructose (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (52 g)
Trial: 27099245
Drug: Sucrose (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (65 g)
Trial: 27099245
Drug: Sucralose (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (0.1 g)
Trial: 25263326
Drug: Blueberry treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry treatment (300 g of blueberry) + smoking
Trial: 25263326
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (300 mL of water with sugar) + smoking
Trial: 22215709
Drug: Purified serum
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified serum IgG from patients with β2 and/or M3 receptor agonistic activity